Case Form
Find Out if You Potentially Qualify for a Financial Reward by filling out the form.
August 2020, Teva Pharmaceutical Industries Limited (“Teva”) received approval from the U.S. Food and Drug Administration to market an off-patent version of Korlym, a best-selling Corcept product. Then on February 20, 2025, Seeking Alpha reported that a group of health insurers had filed a lawsuit against Corcept in California, accusing Corcept of manipulating the patent process in its efforts to “vigorously enforce” its intellectual property rights linked to Korlym, in an effort to stifle Teva’s generic product launch.
Following this news, Corcept’s stock price fell over 11% on the same day.